Yong Fang

机构：Sir Run Run Shaw Hospital, Tongji Hospital, Huazhong University of Science and Technology, Zhejiang University

发表论文 49 篇 · 总被引 292 次 · h-index 9

代表论文

• Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors (2024 · Cell · 被引 102)
• PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF–caspase 8–GSDMD/E axis in ovarian cancer (2024 · Journal for ImmunoTherapy of Cancer · 被引 40)
• Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition) ∆ (2024 · Journal of Cancer Research and Therapeutics · 被引 18)
• Safety and anti-tumor activity of BAY 2927088 in patients with HER2 -mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study. (2024 · Journal of Clinical Oncology · 被引 15)
• Trends and Patterns of HIV Transmitted Drug Resistance in China From 2018 to 2023 (2024 · The Journal of Infectious Diseases · 被引 9)
• SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2 -mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease. (2025 · Journal of Clinical Oncology · 被引 8)